Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Vehicle Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

NCT05764161
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Arkansas City, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

NCT05870865
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
ASN008, ASN008 Matching Vehicle
Drug · Other
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 9:20 AM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317
View directory record Official record
Conditions
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions
PVX-108, Placebo
Biological
Lead sponsor
Aravax Pty Ltd
Industry
Eligibility
4 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494
View directory record Official record
Conditions
Alzheimer's Disease or Vascular Dementia
Interventions
BAC treatment, Matched vehicle
Drug
Lead sponsor
Charsire Biotechnology Corp.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 28, 2026, 9:20 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Results available

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT04210375
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
JK07, Matching Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Tucson, Arizona • Stanford, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

NCT03395340
View directory record Official record
Conditions
Graft Versus Host Disease, JNS Kinase, Topical Administration
Interventions
Ruxolitinib 1.5% cream, vehicle cream
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
12 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

NCT03099304
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 28, 2026, 9:20 AM EDT
Not listed Phase 3 Interventional

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Acne Treatment in Children Ages 9 to 11

NCT00907335
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Retin-A Micro 0.04% facial acne treatment, Vehicle control
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Encino, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 4 Interventional

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

NCT05142267
View directory record Official record
Conditions
Opioid Use Disorder, Back Pain, Stress
Interventions
Placebo, Oxycodone, Naloxone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

NCT00422188
View directory record Official record
Conditions
Lipoma
Interventions
Deoxycholic Acid Injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 28, 2026, 9:20 AM EDT
Recruiting Phase 2 Interventional

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Delgocitinib cream, Vehicle cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Douglasville, Georgia • West Bloomfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

NCT04030962
View directory record Official record
Conditions
Dry Eye Disease, Dry Eye Syndrome
Interventions
AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
View directory record Official record
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 28, 2026, 9:20 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 28, 2026, 9:20 AM EDT